Sector Expert: Lawrence Mayer

Celator Pharmaceuticals Inc.

Image: Lawrence Mayer

Lawrence Mayer, Ph.D., Celator's founder, president and chief scientific officer, has played a lead role in the discovery and development of numerous anticancer drugs, several of which achieved market approval. Dr. Mayer held senior management positions at the Canadian Liposome Company and QLT Inc. before joining the BC Cancer Agency, where he directed the Investigational Drug Program. Dr. Mayer has authored more than 250 publications and has more than 35 patents either awarded or pending. Dr. Mayer received his bachelor of science degree summa cum laude from Wartburg College and his Ph.D. degree from the University of Minnesota.



Recent Interviews

Celator's New Drug Combo Will Revolutionize AML Standard of Care: Scott Jackson and Lawrence Mayer (4/22/15)

Celator Pharmaceuticals Inc.'s remarkable drug combination strategy has produced a cancer-fighting duo endowed with a coveted fast-track designation. Scott Jackson, the company's CEO, and Lawrence Mayer, president, chief scientific officer and founder, tell The Life Sciences Report about what sets Celator apart, and reveal profit-generating milestones that investors should keep on their scopes.



Due to permission requirements, not all quotes are shown.